+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Gamma-Aminobutyric Acid-Induced Elevation of Intracellular Calcium Concentration in Pituitary Cells of Neonatal Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Gamma-aminobutyric acid (GABA) increased intracellular calcium concentration ([Ca<sup>2+</sup>]<sub>i</sub>) of newborn rat pituitary cells in suspension measured by theFURA-2 method. The effect of GABA was dose dependent in the range of 0.1-10 µ M. This effect diminished with postnatal age as measured at days 2, 14 and 21, and in adult animals. The GABA stimulation was mimicked by muscimol; in contrast, baclofen (up to 100 µ M) was ineffective. Picrotoxin, a GABAa antagonist interacting with GABA-activated chloride ionophores, caused a dose-dependent inhibition of the [Ca<sup>2+</sup>]<sub>i</sub> elevating effect of 100 µ M GABA or muscimol. These observations indicate the involvement of GABAa type receptors. The GABA or muscimol effect on [Ca<sup>2+</sup>]<sub>i</sub> was antagonized by nifedipine (10 µ M) or verapamil (50 µ M), and completely abolished in the presence of 4 ml EGTA (low-calcium medium). The findings indicate the presence of depolarizing GABAa receptors on neonatal rat pituitary cells. It seems very likely that the mechanism by which GABA receptor occupation results in elevated [Ca<sup>2+</sup>]<sub>i</sub> is a membrane depolarizaion by increased Cl<sup>–</sup> conductance followed by calcium influx through L-type voltage-dependent calcium channels.

          Related collections

          Author and article information

          S. Karger AG
          08 April 2008
          : 57
          : 6
          : 1028-1034
          aHeim Pál Pediatric Hospital and bInstitute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary
          126467 Neuroendocrinology 1993;57:1028–1034
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article